Monographie de FOQUEST®. Elvium Life Sciences. 28 septembre 2022.
CADDRA - Canadian ADHD Resource Alliance. Lignes directrices
canadiennes sur le TDAH, 4.1 édition. Toronto (Ontario); CADDRA, 2020.
Weiss MD et coll. Efficacy and safety of a long-acting multilayer-release methylphenidate formulation
(PRC-063) in the treatment of adolescent Attention-Deficit/Hyperactivity Disorder: a randomized,
double-blind clinical trial with a 6-Month open-label extension. J
Child Adolesc Psychopharmacol 2021;31(9):610-622.
Weiss MD et coll. Efficacy and safety of PRC-063, extended-release multilayer methylphenidate in adults
with ADHD including 6-month open-label extension. J Attent Disor
2021;25(10):1417-1428.
Monographie de CBiphentin®. Elvium Life Sciences. 2 septembre 2021.
Monographie de CConcerta®. Janssen Inc. 13 mai 2022.
Wigal SB et coll. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34(1):47-53.
Reiz JL et coll. Comparative bioavailability of single-dose methylphenidate from a multilayer-release
bead formulation and an osmotic system: A two-way crossover study in healthy young adults. Clin Ther 2008;30(1):59-69.